Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06136585 · ClinicalTrials.gov registry record · Phase 3
Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial
A Phase 3 study of Neuromuscular Blocks, sponsored by The Cleveland Clinic.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06136585 is a Phase 3 study of Neuromuscular Blocks that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 80 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06136585, a Phase 3 study of Neuromuscular Blocks, is actively recruiting participants, sponsored by The Cleveland Clinic.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators propose a single-center, assessor-Blinded, parallel group randomized trial to compare the efficacy of reversal of rocuronium induced neuromuscular blockade by sugammadex versus neostigmine in patients undergoing Endoscopic retrograde cholangiopancreatography at Cleveland Clinic Fairview Hospital.
Conditions Studied
Interventions
- DRUG 2 mg/kg sugammadex
- DRUG 0.07 mg/kg neostigmine
Study Locations (1)
Ohio
- Cleveland Clinic Fairview Hospital - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06136585
The ClinicalTrials.gov registry entry for NCT06136585 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuromuscular Blocks appearing as the primary indexed condition, and to 2 interventions - of which 2 mg/kg sugammadex is the first listed.
NCT06136585 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06136585 about?
NCT06136585 is a clinical study titled "Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial". The investigators propose a single-center, assessor-Blinded, parallel group randomized trial to compare the efficacy of reversal of rocuronium induced neuromuscular blockade by sugammadex versus neostigmine in patients undergoing Endoscopic retrograde cholangiopancreatography at Cleveland Clinic Fai...
What is the current status of trial NCT06136585?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2024-06-01. Estimated completion is 2026-12-31.
What conditions does trial NCT06136585 study?
This clinical trial studies the following conditions: Neuromuscular Blocks.
What interventions are being tested in trial NCT06136585?
The interventions under investigation include: 2 mg/kg sugammadex (DRUG), 0.07 mg/kg neostigmine (DRUG).
Who is sponsoring clinical trial NCT06136585?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06136585 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.